A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs 2 fluorofucose (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 31 Mar 2017 Last checked agaisnt ClinicalTrials.gov record.
- 27 Mar 2017 Planned primary completion date changed from 1 May 2018 to 1 Jul 2019.
- 09 Feb 2017 Status changed from not yet recruiting to recruiting, as reported in a Seattle Genetics media release.